How To Write A Thyroid Cancer Care Plan

Transcription

1 THYROID NSSG Wednesday 29 June 2011, 12:00pm The Board Room, Evolve Business Centre Video link with Carlisle M I N U T E S Present: Nicola Armstrong, Thyroid Cancer Nurse Specialist, Newcastle Hospitals NA Richard Bliss, Consultant Surgeon, Newcastle RB Alison Comett, Macmillan Head & Neck Specialist Nurse, South Tees AC Wael Elsaify, Consultant, South Tees WE Louise Hobson, Cancer Modernisation Lead, Newcastle Hospitals LH Sarah Johnson, Consultant Pathologist, Newcastle Hospitals SJ Ujjal Mallick, Lead Clinician Thyroid, Newcastle Hospitals UKM Sath Nag, Consultant Endocrinologist, South Tees SaN Vinidh Paleri, Consultant Surgeon, Newcastle Hospitals VP Stewart Pattman, SpR Chemical Pathology/Metabolic Medicine, Newcastle Hospitals SP Suzanne Thompson, Cancer Modernisation Manager, NECN ST Via Video Link: Mike Williams, Consultant Surgeon, North Cumbria MW Bridget Workman, Research Manager, NCRN North BW In Attendance: Ann Bassom, Network Coordinator, NECN ABa Apologies: Steve Ball, Senior Lecturer in Endocrinology, Newcastle SB Kate Farnell, Patient Thyroid Cancer Advisor, Butterfly Trust KF Tom Lennard, Consultant Surgeon, Newcastle Hospitals TL Petros Perros, Consultant Endocrinologist, Newcastle PP Jo Preston, Service Improvement Facilitator, NECN JP Richard Quinton, Consultant Endocrinologist, Newcastle Hospitals RQ Richard Rigby, GP, Redcar & Cleveland PCT RR Michelle Shield, MDT Co-ordinator, Newcastle Hospitals MS Andrew Welsh, Consultant, Newcastle Hospitals AW 1. Welcome & Apologies Action UKM welcomed everyone to the meeting and introductions were made. Apologies were noted as above. 2. Minutes from Previous Meeting 07/07/10 With an amendment to agenda item 3 to read that the group discussed and agreed to adopt this method of cytology reporting the minutes were agreed as a correct record of the meeting. 3. Action Points from Last Meeting Routine Pregnancy Testing 1

2 UKM referred to national debates regarding routine pregnancy testing and suggested this is discussed further outside of this meeting to progress. - Sorafenib UKM reported that sorafenib had been rejected by NECDAG and another submission is being made. - Patient Representative SN reported that he will be discussing with CNSs to see if anyone has expressed an interest in joining as a second patient representative. Thyroglobulin Assay UKM reported that this audit is complete and will be presented later in the meeting. UKM confirmed that a second network wide audit regarding tomotherapy for thyroid cancer has been agreed. It is due to be completed by the end of the year with an aim to showcase in September CNS Appointment UKM confirmed the appointment of NA as a Thyroid cancer nurse specialist in Newcastle. - Audit It was noted that the survival audit will be continued over the next year however there are some technical problems to resolve. UKM and RB to meet to discuss the problems. 5. Clinical Work Programme i. Developments Peer Review Following the peer review external verification process of Head &Neck and Thyroid services in November 2010 the following areas were deemed to be non-compliant: - Oversight of Head & Neck Cancer for the whole network - Network agreed imaging guidelines for Thyroid cancer - Network agreed pathology guidelines for Thyroid cancer The group was presented with the format options provided in the measures 2

3 and following discussion format 2 was supported. The group recommended that the Head & Neck and Thyroid Chairs should be members of both groups and that the terms of reference reflect clear links between the groups. Awareness & Early Diagnosis ST reported on a Thyroid cancer awareness campaign to be held in September. Butterfly Thyroid Cancer Trust is working in partnership with the Thyroid Cancer Care Team at NCCC to promote this campaign and a neck check event will be held in the Metro Centre on Saturday 24 September. Further details attached to these minutes. Awareness Campaign ST informed members on the outcome of a 2 day accelerated solutions event held in April and the Be Clear on Cancer Campaign. Neck Check Clinic ii. Audit Presentation Beckman Platform SP gave a presentation and the group noted the actions outlined on the last slide (attached to these minutes). TG Presentation iii. Guidelines Network Imaging / Pathology Guidelines SJ agreed to review the pathology guidelines which are due to be uploaded by the end of August. Imaging guidelines to be reviewed by Dave Richardson. SJ DR Standardised Network Clinical Guidelines UKM confirmed that the NSSG previously adopted and follow the American Thyroid Association 2009 guidelines alongside the regional management pathway as well as the BTA 2007 guidelines. iv. Research & Trials The group noted the portfolio and recruitment report circulated with the agenda. The NSSG agreed to the following programme of improvement for MDTs - to improve equity of access to trials across the network. 3

4 - To continue to promote the industry portfolio. - MDT to identify and record potential trial patients. - NECN portfolio to be uploaded to the web particularly of interest to TYA MDT who may have potential patients to discuss. BW also informed members of the National Institute of Health Research high level objectives which were noted as follows: As part of the NIHR Clinical Research Network, the North of England cancer Research Networks are working to achieve six High Level Objectives between now and 2015, which have been agreed with the Department of Health. These are: 1. To double the number of participants recruited into NIHR CRN Portfolio studies( Not applicable to cancer studies ) 2. To increase the proportion of studies in the NIHR Clinical Research Network Portfolio delivering to time and target 3. To increase the percentage of commercial contract studies delivered through the NIHR CRN 4. To reduce the time taken to achieve NHS permission through the Coordinated System for gaining NHS Permission (CSP) for NIHR studies 5. To reduce the time taken to recruit first participant into NIHR CRN Portfolio studies (First patient must be recruited within 30 days of trial opening) 6. To increase the percentage of NHS Trusts participating in NIHR CRN Portfolio studies(we already have trials portfolios in all trusts ) Reporting against these objectives will begin in April 2011 and the networks will be working with Local trusts to performance manage these. UKM noted that Hi-Lo has now closed and a new trial called ION is to be launched in August. UKM agreed to forward the details to BW. UKM asked for assistance to enable industry trials to be set up and BW agreed to support with Chris Baron and Julie Charlton. It was noted that we recruited the highest number of patients to the Hi-Lo clinical trial in the country. v. NECDAG vi. Clinical Governance issues There were no issues raised. 6. National Updates Nothing to report. 4

5 7. User Involvement 8. Any Other Business - Adrenal Cancer Group UKM suggested establishing a network wide adrenal group which was supported. SB/RB - Visit UKM reported that Dr Naifa, Assistant Professor Endocrinology, Houston, is visiting the area and he will circulate the dates for interest. Probably 21 st or 22 nd July at the Freeman Hospital. UKM - Chair UKM asked members for any expressions of interest for the position of Chair of this NSSG. ALL 9. Agreed Dates of Future Meetings To be confirmed - preferably a Wednesday lunchtime at Evolve. 10. Minutes Signed Off / Close of Meeting The group reviewed the minutes and agreed them as a correct record of the meeting. 5